UK markets close in 4 hours 35 minutes
  • FTSE 100

    7,497.90
    +28.12 (+0.38%)
     
  • FTSE 250

    21,736.16
    -136.92 (-0.63%)
     
  • AIM

    1,086.37
    -10.92 (-1.00%)
     
  • GBP/EUR

    1.1989
    +0.0018 (+0.15%)
     
  • GBP/USD

    1.3382
    -0.0080 (-0.60%)
     
  • BTC-GBP

    27,399.47
    -1,140.34 (-4.00%)
     
  • CMC Crypto 200

    836.01
    -19.80 (-2.31%)
     
  • S&P 500

    4,349.93
    -6.52 (-0.15%)
     
  • DOW

    34,168.09
    -129.61 (-0.38%)
     
  • CRUDE OIL

    87.66
    +0.31 (+0.35%)
     
  • GOLD FUTURES

    1,807.60
    -22.10 (-1.21%)
     
  • NIKKEI 225

    26,170.30
    -841.03 (-3.11%)
     
  • HANG SENG

    23,807.00
    -482.90 (-1.99%)
     
  • DAX

    15,363.78
    -95.61 (-0.62%)
     
  • CAC 40

    6,956.01
    -25.95 (-0.37%)
     

Emendo Biotherapeutics to Present New Data at 63rd ASH Annual Meeting & Exhibition

·1-min read

NEW YORK, December 08, 2021--(BUSINESS WIRE)--Emendo Biotherapeutics, a next-generation CRISPR company expanding the reach of gene editing therapeutics, will be presenting a poster at the annual American Society of Hematology conference in Atlanta, taking place December 11-14, 2021. The poster will present data from a CRISPR-based ex vivo strategy involving allele-specific excision of the mutant ELANE allele responsible for severe congenital neutropenia.

Poster Presentation: #3122 - Safe and Efficient Engraftment of CRISPR-based ELANE Mono-Allelic Knocked Out HSCs in Mice: Evidence for a Novel Treatment for ELANE Neutropenia

Session Name: 201. Granulocytes, Monocytes, and Macrophages: Poster III

Session Date and Time: Monday, December 13, 2021, 6:00 p.m - 8:00 p.m.

Location: Hall B5, Georgia World Congress Center

Presenter: Vahagn Makaryan

About Emendo Biotherapeutics
EmendoBio is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. EmendoBio’s novel nuclease discovery platform broadens the targetable range of the genome while its target-specific optimization platform enables highly precise editing, including allele specific editing, while maintaining high efficiencies. The capabilities of the OMNI technology platforms, along with deep expertise in genomic medicine, protein engineering and therapeutic development, provide EmendoBio with a unique advantage when addressing indications within hematology, oncology, ophthalmology and other disease areas. For more information please visit us at www.emendobio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211208006008/en/

Contacts

Zuri McClelland
HDMZ
Emendo.pr@hdmz.com
312-506-5214

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting